Moenomycin A Derivatives, their preparation, and use as antibacterial products

Abstract: New derivatives of moenomycin A, their process of preparation, and their use as antibacterial products. wherein R is a radical Ra being an hydrogen atom or an alkyl radical up to 8 carbon atoms, R1 being an hydrogen atom, an optionally substituted alkyl radical linear or branched up to 30 carbon atoms, saturated or unsaturated or an optionally substituted aryl radical up to 14 carbon atoms, or R is a radical R2 being an hydrogen atom or an alkyl radical linear or branched, saturated or unsaturated, up to 30 carbonatoms R3 being an hydrogen atom or an alkyl radical up to 12 carbon atoms. The compounds of formula have antibacterial properties.

Description: The invention relates to new derivatives of moenomycin A, their process of preparation, and their use as antibacterial products. The invention relates to compounds of formula (1) wherein R is a radical Ra being an hydrogen atom or an alkyl radical up to 8 carbon atoms, R1 being an hydrogen atom, an optionally substituted alkyl radical linear or branched up to 30 carbon atoms, saturated or unsaturated or an optionally substituted aryl radical up to 14 carbon atoms, or R is a radical R2 being an hydrogen atom or an alkyl radical linear or branched saturated or unsaturated up to 30 carbonatoms, R3 being an hydrogen atom or an alkyl radical up to 12 carbon atoms. The aryl is preferably phenyl or naphtyl. Examples of alkyl, alkenyl or alkynyl are preferably methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, terbutyl, octyl, decyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, octadecyl, vinyl, ethynyl, propynyl, propargyl, cyclobutyl, cyclopentyl or cyclohexyl. Among the preferred compounds of formula I are those wherein R is a radical Ra and R1 being defined as above for exemple those wherein Ra is an hydrogen atom and those wherein R1 is an aryl radical substituted by an alkyl radical in position para or a radical Among the preferred compounds of formula I are also those wherein R is a radical R2 and R3 being defined as above, for example compounds, wherein R2 is an alkyl radical comprising between 7 and 18 carbon atoms. Among the preferred compounds of formula are compounds the preparation of which is described hereunter and more specially products of examples 4, 5 and 6. The antibiotic compositions of the invention are comprised of an antibiotically effective amount of a compound of formula I and its non-toxic, pharmaceutically acceptable acid addition salts and an inert pharmaceutical carrier. The compositions may be in the form of tablets, dragees, capsules, granules, suppositories, ointments, creams, gels and injectable solutions or suspensions. Examples of suitable pharmaceutical carriers or excipients are talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents and preservatives. There compositions can also be presented in the form of a powder intended to be dissolved extemporaneously in a suitable vehicle, for example apyrogenic sterile water. The compositions possess a very good antibiotic activity on gram⊕ bacteria such as S.aureus, S. pyogenes, or E. Faecium. They are useful in the treatment of infections caused by theses germs particularly preferred are compositions using the compounds of Examples 4, 5 and 6. The novel method of the invention for treating bacterial infections in warm-blooded animals, including humans, comprises, administering to warm-blooded animals an antibiotically effective amount of a compound of formula I or its non-toxic, pharmaceutically acceptable acid addition salts. The compounds may be administered buccally, rectally, parenterally or topically by application to the skin or mucous membrane. The usual daily dose is 1 mg to 1000 mg depending on the condition treated, the specific compound administered and the method of administration. The process of the invention for the preparation of compounds of formula I comprises reacting moenomycin A to an ozonolysis reaction ,obtaining the compound of formula II then submitting the compound of formula II to the action of a reagent or several reagents capable of remplacing by the radical CHR, and obtaining the corresponding compound of formula I. For example, the invention relates to a process wherein the compound of formula II is reacted with an amine of formula III. As a reduction agent, NaBH 3 CN may be used. As an ambodiment of the invention there is a process wherein a compound of formula II is submitted to an allylhalogenide in presence of indium powder to get the compound of formula I wherein R is a radical wherein R is a radical R2 and R3 being defined as above. The compound of formula II is an objet of this invention. The invention relates also to compounds of formula. I as feed additives. Another objet of the invention is feed additives including as antibacterial products at least one compound of formula I.. The feed additives are preferably administered to the animals orally in the form of tablets, granules or powders incorporated into the feed for pigs or calves prepared by the known procedures of such products but they may also be administered parenterally. The feed mixture will vary depending on the animal species but usually contains cereals, sugars, grains, arachidic and tournsole and soybean press cake, flours of animal origin such as fish flour, amino acids of synthesis, mineral salts, vitamins and antioxidants. In the following examples, there are described several preferred embodiments to illustrate the invention. However, it is to be understood that the invention is not intended to be limited to the specific embodiments. In the NMR spectra the proton and carbon are assigned according to the following convention. Example 1 : Hexadecylamine derivative Step A Synthesis of the aldehyde of moenomycin A (P) A solution of moenomycin A (1061.7 mg, 671 pmol) in 15 ml of methanol was cooled to -78°C. The solution was saturated with ozonised oxygen (Fischer OZON 502, flow rate 50 l/h = 2 g/h O 3 ) at -78 °C until the solution reach a light blue colour (ca. 30 min). The precipitated product was filtered after warming up to room temperature and rinsed with methanol. The product was solved in water and lyophilised to give the expected product in 98 % (786.4 mg) yield. C 41 H 66 N 5 O 33 P1187.9 g/mol MS: m/z (electron spray - negative mode) 1186 ([M-H] - ), 1144 ([M-H-CH 2 CO] - ), 592 ([M-2H] 2- ), 571 ([M-2H-CH 2 CO] 2- ) 1 H-NMR δ = 1.20 (s, CH 3 -4 F ), 1.28 (d, CH 3 -6 C ), 2.00 (s,NHCOCH 3 E ), 2.07 (s,NHCOCH 3 C ), 4.44 (s, H-5 F ), 4.48 (d, H-1 C ), 5.68 (q, H-1 F ) Step B hexadecylamine derivative of the aldehyde (P) To a solution of 3 (55.6 mg, 47 µmol) in a mixture of 300 µl water, 100 µl phosphate buffer (pH 7, 0.2 M) and 800 µl methanol 46.1 mg (94 µmol) of 1-hexadecylamine solved in 800 µl methanol and 6 mg (94 µmol) NaBH 3 CN solved in 100 µl methanol were added. The pH of the mixture was adjusted with 1 N acetic acid to 6.5. The mixture was stirred for 3 days at room temperature. The crude mixture was directly applied on a Sephadex® LH-20 column (10 g/ H 2 O-CH 3 OH 1 :4). All fractions containing the product were collected, evaporated and freeze dried. The crude product was purified on an silica gel column using AcOEt/ i-PrOH/H 2 O (6 :4 :3) as eluent followed by another Sephadex LH-20 column to remove traces of silica gel. The residue was taken up and freed from a second equivalent of 1-hexadecylamine using a DOWEX® (type : 50 W X8) column (water). After solvent evaporation and lyophilisation the product 10 was obtained in 63 % (42.1 mg) yield. C 57 H 101 N 6 O 32 P 1413.44 g/mol MS: m/z (electron spray - positive mode) 1414.3 ([M+H] + ), 1436.3.9 ([M+Na] + ), 729.7 ([M+2Na] 2+ ), 707.9 ([M+2H] 2+ ) 1 H-NMR (600 MHz, D 2 O): δ = 0.76 (t, CH 3 -16 I ), 1.12 (s, CH 3 -4 F ), 1.16-1.28 (m, CH 2 -3 I -15 I ), 1.29 (d, CH 3 -6 C ), 1.62 (dd, CH 2 -2 I ), 1.93 (s, NHAc C ), 1.99 (s, NHAc E ), 2.98 (t, CH 2 -I 1 ), 3.20 (t, 2-H D ), 3.84 (d, 6-H x D ), 4.12 (s, 5-H F ), 4.41 (d, 1-H D ), 4.49 (d, 2-H C ), 4.92 (d, 3-H F ), 5.71 (q, 1-H F ) 13 C-NMR (150 MHz, D 2 O) : δ = 14.4 (C-16 I ), 15.1 (CH 3 -4 F ), 17.1 (CH 3 -C 6 ), 22.7 (NHCO C H 3 E ), 22.8 (NHCO C H 3 C ), 23.1 (CH 2 -15 I ), 27.0 (CH 2 -I 2 ), 29.6-30.4 (CH 2 -3 I -13 I ), 32.4 (CH 2 -14 I ), 42.7 (CH 2 -1 I ), 42.8 (CH 2 -NH I ), 55.8 (C-2 E ), 55.9 (C-2 C ), 61.2 (C-6 D ), 69.3 (C-6 E ), 70.2 (C-4 B ), 71.0 (C-4 D ), 71.5 (C-2 B ), 72.5 (C-5 C ), 72.6 (C-3 E ), 72.8 (C-3 C ), 73.2 (C-5 F ), 73.5 (C-4 F ), 73.6 (C-2 D ), 73.9 (C-5 B ), 74.6 (C-3 F ), 75.3 (C-3 D ), 76.2 (C-5 D ), 76.4 (C-2 F ), 80.2 (C-4 E ), 83.5 (C-4 C ), 94.7 (C-1 F ), 101.7 (C-1 C ), 102.4 (C-1 E ), 103.0 (C-1 B ), 103.7 (C-1 D ), 158.6 (C-3 F ), 173.1 (C-5 B ), 173.6 (C-5 C ), 174.9 (C-2 E ), 175.0 (C-2 C ) Example 2 Synthesis of the allyl derivative of the aldehyde (P) To a solution of product P (21.3 mg, 18 µmol) in a mixture of 600 µl of water and 400 µl methanol allylbromide (4.3 mg, 36 µmol) and indium (4.1 mg, 36 µmol) were added. The mixture was stirred rapidly for 12 h at room temperature. The solvents were removed under reduced pressure from the crude mixture and the residue was resolved in water, after filtration (MILLEX-LCR 13 ®) the filtrate was purified on a Sephadex® PD-10 column. The expected product was obtained in 80.2 % (18.2 mg) yield after lyophilisation. C 44 H 72 N 5 O 33 P - 1230.1 g/mol 1 H-NMR δ = 1.24 (s, CH 3 -4 F ), 1.38 (d, CH 3 -6 C ) , 2.03 (s,NHCOCH 3 E ), 2.09 (s,NHCOCH 3 C ) , 4.44 (s, H-5 F ), 4.57 (d, H-1 C ), 4.59 (d, H-1 E ), 5.00 (d, H-3 F ), 5.85-5.95 (m, -C H =CH 2 ), 5.79 (q, H-1 F ) Example 3 Synthesis of the ammonia derivative of the aldehyde (P) To a solution of product P (99.7 mg, 83 µmol) in an mixture of 400 µl of water and 1600 µl of methanol a solution of ammonium acetate (64.7 mg, 830 µl) and NaBH 3 CN (5.35 mg, 160 µmol) in 400 µl of methanol were and the solution stirred for 48 h at room temperature. The crude mixture was applied to a Sephadex LH-20 column to give the expected product 30 in 78 % (77.8 mg) yield. C 41 H 69 N 6 O 32 P1188.99 g/mol MS: m/z (electron spray - negative mode) 1187.0 ([M-H] - ), 593.3 ([M-2H] 2- ) 1 H-NMR (200 MHz, D 2 O): δ = 1.20 (s, CH 3 -4 F ), 1.28 (d, CH 3 -6 C ), 2.00 (s,NHCOCH 3 E ), 2.07 (s,NHCOCH 3 C ), 4.19 (s, H-5 B ), 4.95 (d, H-3 F ), 5.8 (q, H-1 F ) 13 C-NMR (150 MHz, D 2 O) : δ = 15.2 (CH 3 -4 F ), 17.1 (CH 3 -C 6 ), 22.8 (NHCO C H 3 E ), 22.9 (NHCO C H 3 C ) , 39.8 (CH 2 -NH I ), 55.8 (C-2 E ), 55.9 (C-2 C ), 61.2 (C-6 D ), 69.3 (C-6 E ), 70.1 (C-4 B ), 71.0 (C-4 D ), 71.5 (C-2 B ), 72.4 (C-5 C ), 72.6 (C-3 E ), 72.9 (C-3 C ), 73.1 (C-3 B ), 73.3 (C-5 F ), 73.5 (C-4 F ), 73.6 (C-2 D ), 73.9 (C-5 B ), 74.5 (C-3 F ), 75.2 (C-3 D ), 76.2 (C-5 D ), 76.4 (C-2 F ), 80.1 (C-4 E ), 83.5 (C-4 C ), 94.8 (C-1 F ), 101.6 (C-1 C ), 102.6 (C-1 E ), 103.0 (C-1 B ), 103.6 (C-1 D ), 158.6 (C-3 F ), 173.1 (C-5 B ), 173.6 (C-5 C ), 174.7 (C-2 E ), 174.9 (C-2 C ) Example 4 : 3-carbamate 1-[(2R)-2-carboxy-2-[[(3,7,11,15-tetramethyl-2-hexadecenyl)amino]ethoxy]ethyl hydrogen phosphate] 0-.beta.-D-glucopyranosyl-(1.fwdarw.6)-O-[O-phosphate] O-.beta.-D-glucopyranosyl-(1.fwdarw.6)-O-[O-(.beta.-D-galactopyranuronamidosyl)-(1.fwdarw.4)-2-(acetylamino)-2,6-dideoxy-.beta.-D-glucopyranosyl-(1.fwdarw.4]-O-2-(acetylamino)-2-deoxy-.beat.-D-glucopyranosyl-(1.fwdarw.2)-4-C-methyl-.alpha.-D-Glucopyranuronamide Synthesis of the [ 15 N]-E-phytolamine derivative of the aldehyde (P) To a solution of product P (54.3 mg, 46 µmol) in a mixture of 300 µl water, 100 µl phosphate buffer (pH 7, 0.2 M) and 800 µl methanol 27.1 mg (92 µmol) of [ 15 N]-E-phytolamine solved in 800 µl methanol and 5.7 mg (92 µmol) NaBH 3 CN solved in 100 µ l methanol were added. The pH of the mixture was adjusted with 1 N acetic acid to 7. The mixture was stirred for 48 h at room temperature. The crude mixture was directly applied on a Sephadex® LH-20 column (10 g/ H 2 O-CH 3 OH 1 :4). All fractions containing the product were collected, evaporated and freeze dried. The crude product was purified on an silica gel column using AcOEt/ i-PrOH/H 2 O (6 :4 :3) as eluent followed by another Sephadex LH-20 column to remove traces of silica gel. The residue was taken up and freed from a second equivalent of [ 15 N]-E-phytolamine using a DOWEX® (type : 50 W X8) column (water). After solvent evaporation and lyophilisation the product 14 was obtained in 19 % ( 13.2 mg) yield. C 61 H 107 N 6 O 32 P 1468.53 gl/mol MS: m/z (electron spray - positive mode) 1508.6 ([M+K] + ), 1489.4 ([M+Na] + ), 754.1 ([M+2K] 2+ ) 1 H-NMR (600 MHz, CD 3 OD): δ = 0.80-0.82 (s, CH 3 - 16,17 I ), 0.83 (s, CH 3 - 18,19 I ), 1.17 (s, CH 3 -4 F ), 1.3 (CH 2 -I), 1.35 (d, CH 3 -6 C ) , 1.71 (s, CH 3 -20 I ) 1.94 (s,NHCOCH 3 E ), 2.00 (s,NHCOCH 3 C ), 2.03 (t, C H 2 -CH=CH-), 5.03 (d, 3-H F ), 5.35 (-C H =C H I ), 5.96 (q, H-1 F ) Example 5 : 3-carbamate 1-[(2R)-2-carboxy-2-[[(4-dodecylphenyl))amino]ethoxy]ethyl hydrogen phosphate] 0-.beta.-D-glucopyranosyl-(1.fwdarw.6)-O-[O-(.beta.-D-galactopyranuronamidosyl)-(1.fwdarw.4)-2-(acetylamino)-2,6-dideoxy-.beta.-D-glucopyranosyl-(1.fwdarw.4]-O-2-(acetylamino)-2-deoxy-.beat.-D-glucopyranosyl-(1.fwdarw.2)-4-C-methyl-.alpha.-D-Glucopyranuronamide Synthesis of the dodecylaniline derivative of the aldehyde (P) To a solution of product P (53.4 mg, 45 µmol) in a mixture of 300 µl water, 100 µl phosphate buffer (pH 7, 0.2 M) and 800 µl methanol 23.5 mg (90 µmol) of dodecylaniline solved in 800 µl methanol and 5.7 mg (90 µmol) NaBH 3 CN solved in 100 µl methanol were added. The pH of the mixture was adjusted with 1 N sodium hydroxide to 7. The mixture was stirred for 72 h at room temperature. The crude mixture was directly applied on a Sephadex® LH-20 column (10 g/ H 2 O-CH 3 OH 1 :4). All fractions containing the product were collected, evaporated and freeze dried. The crude product was purified on an silica gel column using AcOEt/ i-PrOH/H 2 O (6 :4 :3) as eluent followed by another Sephadex LH-20 column to remove traces of silica gel. After solvent evaporation and lyophilisation the desired product was obtained in 31 % (20.1 mg) yield. C 59 H 97 N 6 O 32 P1433.43 g/mol Ms : M/Z (Maldi-tof) M+=1432.65 1 H-NMR (600 MHz, D 2 O): δ = 0.77 (t, CH 3 -12 I ), 1.13 (s, CH 3 -4 F ), 1.15-1.22 (CH 2 -3 I -11 I ), 1.28 (d, CH 3 -6 C ), 1.49 (CH 2 -2 I ), 1.95 (s, NHCOCH 3 E ) , 2.01 (s, NHCOCH 3 C ), 2.45 (t, CH 2 -1 I ), 3.22 (2-H D ), 3.66 (6-H y D ), 3.77 ( J =9.9 Hz, 2-H F ), 3.83 ( J =12.5 Hz, 6-H x D ), 4.37 (s, 5-H F ), 4.43 (d, 1-H D ), 4.50 (d, 2-H C ), 4.96 (d, 3-H F ), 5.71 (q, H-1 F ), 6.78 (2-H Ar , 6-H Ar ), 7.07 (3-H Ar , 5-H Ar ) 13 C-NMR (150 MHz, D 2 O) : δ = 14.4 (C-12 I ), 15.5 (CH 3 -4 F ), 17.2 (CH 3 -C 6 ), 23.0 (NHCO C H 3 E ), 23.1 (NHCO C H 3 C ), 23.2 (CH 2 -11 I ), 29.6-30.4 (CH 2 -3 I -19 I ), 32.4 (CH 2 -10 I ), 35.5 (CH 2 -1 I ), 46.5 (CH 2 -NH I ), 55.8 (C-2 E ), 55.9 (C-2 C ), 61.2 (C-6 D ), 69.3 (C-6 E ), 70.2 (C-4 B ), 71.0 (C-4 D ), 71.5 (C-2 B ), 72.5 (C-5 C ), 72.6 (C-3 E ), 72.8 (C-3 C ), 73.2 (C-5 F ), 73.5 (C-4 F ), 73.6 (C-2 D ), 73.9 (C-5 B ), 74.6 (C-3 F ), 75.3 (C-3 D ), 76.2 (C-5 D ), 76.4 (C-2 F ), 80.0 (C-4 E ), 83.5 (C-4 C ), 94.7 (C-1 F ), 101.7 (C-1 C ), 102.4 (C-1 E ), 103.0 (C-1 B ), 103.7 (C-1 D ), 117.5 (C-2 I , C-6 I ), 129.5 (C-3' I , C-5' I ), 135.6 (C-4' I ), 143.9 (C-1' I ), 158.6 (C-3 F ), 173.4 (C-5 B ), 173.6 (C-5 C ), 174.7 (C-2 E ), 175.0 (C-2 C ) Example 6 : 3-carbamate 1-[(2R)-2-carboxy-2-[(3-ethenyl-2-hydroxydodecyl)oxy]ethyl hydrogen phosphate] 0-.beta.-D-glucopyranosyl-(1.fwdarw.6)-O-[O-(.beta.-D-galactopyranuronamidosyl)-(1.fwdarw.4)-2-(acetylamino)-2,6-dideowy-.beta.-D-glucopyranosyl-(1.fwdarw.4]-O-2-(acetylamino)-2-deoxy-.beat.-D-glucopyranosyl-(1.fwdarw.2)-4-C-methyl-.alpha.-D-Glucopyranuronamide Synthesis of the E/Z-dodecenylbromide derivative (39) of the aldehyde (P) To a solution of product P (57 mg, 48 µmol) in a mixture of 400 µl of water and 1.6 ml of methanol 59.3 mg (240 µmol) E/Z-dodecenylbromide and 11 mg (96 µmol) indium were added. To this solution ultra sonic was applied for 10 min and rapid stirring for 24 h. The crude mixture was filtered and the filtrate was directly applied on a Sephadex® LH-20 column (10 g/ H 2 O-CH 3 OH 1 :4). All fractions containing the product were collected, evaporated and freeze dried. The crude product was purified on an silica gel column using AcOEt/ i-PrOH/H 2 O (6 :4 :3) as eluent followed by another Sephadex LH-20 column to remove traces of silica gel. After solvent evaporation and lyophilisation the product 39 was obtained in 11 % (6.5 mg) yield. C 53 H 90 N 5 O 33 P 1356.30 g/mol MS: m/z (electron spray - positive mode) 1357.0 ([M+H] + ), 1378.4 ([M+Na] + ), 691.0 ([M+Na] 2+ ), 679.1 ([M+2H] 2+ ) 1 H-NMR δ = 0.9 (t, CH 3 -1 I ) 1.20 (s, CH 3 -4 F ), 1. 25 (s, CH 2 -2-7 I ), 1.38 (d, CH 3 -6 C ) , 2.00 (s,NHCOCH 3 E ), 2.07 (s, NHCOCH 3 C ), 5.4-5.6 (m, -CH=CH 2 ), 5.8 (q, H-1 F ) Example 7 : isomere Z corresponding to example 4 Synthesis of the [ 15 N]-Z-phytolamine derivative of the aldehyde (P) To a solution of 3 (65.2 mg, 55 µmol) in a mixture of 300 µl water, 100 µl phosphate buffer (pH 7, 0.2 M) and 800 µl methanol 48.8 mg (165 µmol) of [ 15 N]-Z-phytolamine solved in 800 µl methanol and 6.9 mg (110 µmol) NaBH 3 CN solved in 100 µl methanol were added. The pH of the mixture was adjusted with 1 N acetic acid to 7. The mixture was stirred for 48 h at room temperature. The crude mixture was directly applied on a Sephadex® LH-20 column (10 g/ H 2 O-CH 3 OH 1 :4). All fractions containing the product were collected, evaporated and freeze dried. The crude product was purified on an silica gel column using AcOEt/ i-PrOH/H 2 O (6 :4 :3) as eluent followed by another Sephadex LH-20 column to remove traces of silica gel. The residue was taken up and freed from a second equivalent of [ 15 N]-Z-phytolamine using a DOWEX® (type : 50 W X8) column (water). After solvent evaporation and lyophilisation the product 13 was obtained in 8 % ( 6.7 mg) yield. C 61 H 107 N 6 O 32 P 1468.53 g/mol MS: m/z (electron spray - positive mode) 1508.6 ([M+K] + ), 1489.4 ([M+Na] + ), 754.1 ([M+2K] 2+ ) 1 H-NMR (600 MHz, CD 3 OD): δ = 0.80-0.82 (s, CH 3 - 16,17 I ), 0.83 (s, CH 3 - 18,19 I ), 1.17 (s, CH 3 -4 F ), 1. 3 (CH 2 -I), 1.35 (d, CH 3 -6 C ), 1.71 (s, CH 3 -20 I ) 1.94 (s,NHCOCH 3 E ), 2.00 (s, NHCOCH 3 C ), 2.09 (t, C H 2 -CH=CH-) , 5.06 (d, 3-H F ), 5.36 (-C H =C H I ),5.97 (q, H-1 F ) So, using the different processes, the following products were prepared Example : Tablets were prepared containing 150 mg of the product of Example 4 or 5 or 6 and sufficient excipient of starch, talc and magnesium stearate for a final weight of 1 g. PHARMACOLOGICAL STUDY OF THE PRODUCTS OF THE INVENTION A) Activity in vitro Method of dilutions in liquid medium. A series of tubes were prepared in which the same amount of sterile nutritive medium was distributed and increasing amounts of the product to be studied was distributed in each tube. Then, each tube was seeded with a bacterial strain and after incubationg for twenty-four hours in an oven at 37° C, the inhibition of growth was determined by transillumination which allowed the minimum inhibiting concentrations (M.I.C.) to be evaluated. Products were tested on many strains inclusing : S. aureus SG511 S. aureus SG511 (+10 % serum) S. aureus Exp54146 S. pyogenes A561 E. faecium M78L Good results were observed specially products of example 4, 5, 6 efficient against S. pyogenes A561 at dose ≤ 1,2 microgramme/ml.

Claims: Compounds of formula 1 wherein R is a radical Ra being an hydrogen atom or an alkyl radical up to 8 carbon atoms, R1 being an hydrogen atom, an optionally substituted alkyl radical linear or branched up to 30 carbon atoms, saturated or unsaturated or an optionally substituted aryl radical up to 14 carbon atoms, or R is a radical R2 being an hydrogen atom or an alkyl radical linear or branched, saturated or unsaturated, up to 30 carbonatoms R3 being an hydrogen atom or an alkyl radical up to 12 carbon atoms. Compounds of formula 1 according to claim 1 wherein R is a radical Ra and R1 being defined as above. Compounds according to claim 2 wherein Ra is an hydrogen atom Compounds according to claim 2 wherein R1 is aryl radical substituted by an alkyl radical in position para or a radical Compounds according to claim 1 wherein R is a radical R2 and R3 being defined as above. Compounds according to claim 5 wherein R2 is an alkyl radical comprising between 7 and 18 carbon atoms. The following compounds according to claim 1 : 3-carbamate 1-[(2R)-2-carboxy-2-[[(3,7,11,15-tetramethyl-2-hexadecenyl)amino]ethoxy]ethyl hydrogen phosphate] 0-.beta.-D-glucopyranosyl-(1.fwdarw.6)-O-[O-(.beta.-D-galactopyranuronamidosyl)-(1.fwdarw.4)-2-(acetylamino)-2,6-dideoxy-.beta.-D-glucopyranosyl-(1.fwdarw.4]-O-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl-(1.fwdarw.2)-4-C-methyl-.alpha.-D-Glucopyranuronamide3-carbamate 1-[(2R)-2-carboxy-2-[[(4-dodecylphenyl))amino]ethoxy]ethyl hydrogen phosphate] 0-.beta.-D-glucopyranosyl-(1.fwdarw.6)-O-[O-(.beta.-D-galactopyranuronamidosyl)-(1.fwdarw.4)-2-(acetylamino)-2,6-dideoxy-.beta.-D-glucopyranosyl-(1.fwdarw.4]-O-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl-(1.fwdarw.2)-4-C-methyl-.alpha.-D-Glucopyranuronamide 3-carbamate 1-[(2R)-2-carboxy-2-[(3-ethenyl-2-hydroxydodecyl)oxy]ethyl hydrogen phosphate] 0-.beta.-D-glucopyranosyl-(1.fwdarw.6)-O-[O-(.beta.-D-galactopyranuronamidosyl)-(1.fwdarw.4)-2-(acetylamino)-2,6-dideowy-.beta.-D-glucopyranosyl-(1.fwdarw.4]-O-2-(acetylamino)-2-deoxy-.beat.-D-glucopyranosyl-(1.fwdarw.2)-4-C-methyl-.alpha.-D-Glucopyranuronamide Process of preparation of compounds according to claim 1 comprising reacting moenomycin A to an ozonolysis reaction, obtaining the compound of formula II then submitting the compound of formula II to the action of a reagent or several reagents capable of remplacing by the radical CHR to obtain the corresponding compound of formula I. Process according to claim 8 wherein the compound of formula II is reacted with an amine of formula III R a and Rb being defined as above,in the presence of reducing agent to obtain the corresponding compound of formula I. Process according to claim 9, wherein the reducing agent is NaBH3CN. Process according to claim 8 wherein a compound of formula II is submitted to an allylhalogenide to get the compound of formula I wherein R is a radical R2 and R3 being defined as above. As a chemical product ,the compound of formula II as defined in claim 8. As antibacterial products, the compounds of any of the claims 1 to 7. Feed additives including as antibacterial products at least one compound of formula I as defined in any of the claims 1 to 7.

Inventors: LAMPILAS MAXIME, VOGEL STEFAN, LAMPILAS, MAXIME, VOGEL, STEFAN
Applicants: HOECHST MARION ROUSSEL INC, HOECHST MARION ROUSSEL
Application year: 1999
Main classification: C07H13
IPC codes: C07H13